Journals Breast Cancer Research and Tre...

Breast Cancer Research and Treatment
Hiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama, Tomomi Fujisawa, Norikazu Masuda, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi
PURPOSE: Neoadjuvant endocrine therapy (NET) is a treatment option for estrogen receptor-positive (ER+) postmenopausal early breast cancer (EBC). This phase III trial evaluated the prognosis of EBC patients treated with/without chemotherapy (CT) following NET. METHODS: ER+/HER2-, T1c-2, and clinically node-negative EBC patients were enrolled in 2008-2013 and treated with endocrine therapy (ET) in weeks 24-28. All patients, excluding those with progressive disease (PD) during NET or ≥ 4 positive lymph nodes after surgery, were randomized to ET for 4...
March 22, 2023: Breast Cancer Research and Treatment
Priya Rastogi, Gong Tang, Saima Hassan, Charles E Geyer, Catherine A Azar, Gustav C Magrinat, J Marie Suga, Harry D Bear, Luis Baez-Diaz, Shakir Sarwar, Jean-Francois Boileau, Adam M Brufsky, Henry R Shibata, Hanna Bandos, Soonmyung Paik, Greg Yothers, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: The primary aim of this randomized neoadjuvant trial in operable, HER2-positive breast cancer, was to determine the efficacy on pathologic complete response (pCR) of substituting lapatinib (L) for trastuzumab (T) or adding L to T, in combination with weekly paclitaxel (WP) following AC. Results on pCR were previously reported. Here, we report data on planned secondary endpoints, recurrence-free interval (RFI) post-surgery, and overall survival (OS). METHODS: All patients received standard AC q3 weeks × 4 cycles followed by WP (80 mg/m2 ) on days 1, 8, and 15, q28 days × 4 cycles...
March 22, 2023: Breast Cancer Research and Treatment
Justin C Brown, Kathleen Sturgeon, David B Sarwer, Andrea B Troxel, Angela M DeMichele, Crystal S Denlinger, Kathryn H Schmitz
PURPOSE: Cancer and its treatments accelerate biological aging. This analysis tested the hypothesis that exercise and diet reduce oxidative stress and prevent telomere shortening in breast cancer survivors. METHODS: In a 2 × 2 factorial design, 342 breast cancer survivors who were insufficiently physically active and had overweight or obesity at enrollment were randomized to one of four treatment groups for 52 weeks: control, exercise alone, diet alone, or exercise plus diet...
March 18, 2023: Breast Cancer Research and Treatment
S Chew Minmin, A Bacotti, Y Chen, C Anders, M Sambade, A M Deal, D Trembath, M J McKee, E Brogi, A D Seidman
PURPOSE: Tumor-infiltrating lymphocytes (TILs) have been positively correlated with response to systemic therapy for triple-negative and HER2 + subtypes and improved clinical outcomes in early breast cancer (BC). Less is known about TILs in metastatic sites, particularly brain metastases (BM), where unique immune regulation governs stromal composition. Reactive glial cells actively participate in cytokine-mediated T cell stimulation. The impact of prior medical therapy (chemotherapy, endocrine, and HER2-targeted therapy) on the presence of TILs and gliosis in human breast cancer brain metastases (BCBM) has not been previously reported...
March 17, 2023: Breast Cancer Research and Treatment
Xuejing Liu, Yanjie Wang, Kun Cao, Lu Yao, Li Hu, Jie Sun, Juan Zhang, Ye Xu, Yuntao Xie
PURPOSE: Multifocal or multicentric (MFMC) breast cancer is mainly focused on breast cancer patients with unknown BRCA status, the incidence and clinical relevance of MFMC disease in BRCA1/2 carriers is less explored to date. Our study was to investigate the incidence of MFMC disease in BRCA1/2 carriers and whether MFMC disease influences local recurrence and clinical outcomes. METHODS: In this retrospective study, 479 breast cancer patients with BRCA1/2 variants and 1437 age-matched noncarriers were enrolled and patients received either breast-conserving therapy (BCT) or mastectomy with or without radiotherapy...
March 17, 2023: Breast Cancer Research and Treatment
Oliver William Scott, Sandar TinTin, Sixten Harborg, Marion J J Kuper-Hommel, Ross Lawrenson, J Mark Elwood
PURPOSE: Statins are the most widely prescribed cholesterol lowering medications and have been associated with both improved and unchanged breast cancer outcomes in previous studies. This study examines the association between the post-diagnostic use of statins and breast cancer outcomes (death and recurrence) in a large, representative sample of New Zealand (NZ) women with breast cancer. METHODS: Women diagnosed with a first primary breast cancer between 2007 and 2016 were identified from four population-based regional NZ breast cancer registries and linked to national pharmaceutical data, hospital discharges, and death records...
March 17, 2023: Breast Cancer Research and Treatment
Leslie V Farland, Siwen Wang, Janet W Rich-Edwards, Audrey J Gaskins, Jorge E Chavarro, Yi-Xin Wang, Rulla M Tamimi, Stacey A Missmer
PURPOSE: Research on infertility and risk of breast cancer has been conflicting, potentially because many well-established breast cancer risk factors, such as pregnancy history, are strongly correlated with infertility. METHODS: We followed participants in the Nurses' Health Study II from 1989 to 2015 (n = 103,080) for the development of invasive breast cancer and calculated Hazard Ratios (HR) and 95% confidence intervals (CI) using Cox regression...
March 16, 2023: Breast Cancer Research and Treatment
Florian Ebner, Jessica Salmen, Davut Dayan, Matthias Kiesel, Regine Wolters, Wolfgang Janni, Achim Wöckel, Manfred Wischnewsky
PURPOSE: Although the incidence of distant relapse is decreasing, 20-30% of patients with early breast cancer die of metastasis. The aim of this study is to characterize patients with metastasis-free survival(MFS) less than 5 years, to analyze the most probable site of metastases according to the internally and externally validated BRENDA-score. The BRENDA-score is a combination of the biological subtype and clinical staging. METHOD: 3832 patients with primary diagnosis of breast cancer and either distant metastatic recurrence within 5 years or MFS ≥ 5 years were assigned to this study...
March 14, 2023: Breast Cancer Research and Treatment
Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Simone Talucci, Diego Bisignano, Alessandro Bressan, Daniela Bellarosa, Corrado Carrisi, Alessandro Paoli, Mario Bigioni, Patrizia Tunici, Clelia Irrissuto, Massimiliano Salerno, Joaquin Arribas, Elisa de Stanchina, Maurizio Scaltriti, Monica Binaschi
PURPOSE: Dysregulation of the PI3K pathway is one of the most common events in breast cancer. Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and phenotypic levels by dissecting and comparing its profile and efficacy in HER2 + breast cancer models with other PI3K inhibitors. METHODS: Models with different genetic backgrounds were used to investigate the pharmacological profile of MEN1611 against other PI3K inhibitors...
March 13, 2023: Breast Cancer Research and Treatment
Caitlin Taylor, Jane Meisel, Aimee J Foreman, Christy Russell, Dipankar Bandyopadhyay, Xiaoyan Deng, Lisa Floyd, Amelia Zelnak, Harry Bear, Ruth O'Regan
PURPOSE: The role of neoadjuvant endocrine therapy in the treatment of patients with early-stage, hormone receptor-positive (HR +) breast cancer is not well defined. Tools to better determine which patients may benefit from neoadjuvant endocrine therapy versus chemotherapy or upfront surgery remain an unmet need. METHODS: We assessed the rate of clinical and pathologic complete response (cCR, pCR) among a pooled cohort of patients with early-stage HR + breast cancer who had been randomized to neoadjuvant endocrine therapy or neoadjuvant chemotherapy in two earlier studies to understand better how outcomes varied by Oncotype DX Breast Recurrence Score® assay...
March 10, 2023: Breast Cancer Research and Treatment
Amber N Hurson, Alina M Hamilton, Linnea T Olsson, Erin L Kirk, Mark E Sherman, Benjamin C Calhoun, Joseph Geradts, Melissa A Troester
BACKGROUND: The PAM50 assay is used routinely in clinical practice to determine breast cancer prognosis and management; however, research assessing how technical variation and intratumoral heterogeneity contribute to misclassification and reproducibility of these tests is limited. METHODS: We evaluated the impact of intratumoral heterogeneity on the reproducibility of results for the PAM50 assay by testing RNA extracted from formalin-fixed paraffin embedded breast cancer blocks sampled at distinct spatial locations...
March 9, 2023: Breast Cancer Research and Treatment
Kate E Dibble, Richard N Baumgartner, Stephanie D Boone, Kathy B Baumgartner, Avonne E Connor
PURPOSE: To determine the associations between ethnicity, age at diagnosis, obesity, multimorbidity, and odds of experiencing breast cancer (BC) treatment-related side effects among long-term Hispanic and non-Hispanic white (NHW) survivors from New Mexico and explore differences by tamoxifen use. METHODS: Lifestyle and clinical information including self-reported tamoxifen use and presence of treatment- related side effects were collected at follow-up interviews (12-15 years) for 194 BC survivors...
March 9, 2023: Breast Cancer Research and Treatment
Annemiek K E van Hemert, Josefien P van Olmen, Liesbeth J Boersma, John H Maduro, Nicola S Russell, Jolien Tol, Ellen G Engelhardt, Emiel J Th Rutgers, Marie-Jeanne T F D Vrancken Peeters, Frederieke H van Duijnhoven
PURPOSE: Neoadjuvant systemic therapy (NST) is increasingly used in breast cancer patients and depending on subtype, 10-89% of patients will attain pathologic complete response (pCR). In patients with pCR, risk of local recurrence (LR) after breast conserving therapy is low. Although adjuvant radiotherapy after breast conserving surgery (BCS) reduces LR further in these patients, it may not contribute to overall survival. However, radiotherapy may cause early and late toxicity. The aim of this study is to show that omission of adjuvant radiotherapy in patients with a pCR after NST will result in acceptable low LR rates and good quality of life...
March 9, 2023: Breast Cancer Research and Treatment
Mmadili N Ilozumba, Lusine Yaghjyan, Susmita Datta, Jinying Zhao, Zhihong Gong, Chi-Chen Hong, Kathryn L Lunetta, Gary Zirpoli, Elisa V Bandera, Julie R Palmer, Song Yao, Christine B Ambrosone, Ting-Yuan David Cheng
BACKGROUND: Physical activity has been shown to affect the mammalian target of rapamycin (mTOR) signaling pathway and consequently breast carcinogenesis. Given that Black women in the USA are less physically active, it is not well understood whether there are gene-environment interactions between mTOR pathway genes and physical activity in relation to breast cancer risk in Black women. METHODS: The study included 1398 Black women (567 incident breast cancer cases and 831 controls) from the Women's Circle of Health Study (WCHS)...
March 8, 2023: Breast Cancer Research and Treatment
Kennedy W Mwangi, Moses K Kamita, Jacqueline W Waweru, Shahin Sayed, Jonine D Figueroa, Stefan Ambs, Konrad J Cios, George Blanck, Francis W Makokha
BACKGROUND: Characterization of the breast cancer (BC) immune response may provide information for a point of intervention, such as application of immunotherapeutic treatments. In this study, we sought to recover and characterize the adaptive immune receptor (IR) recombination reads from genomics files representing Kenyan patients, to better understand the immune response specifically related to those patients. METHODS: We used a previously applied algorithm and software to obtain productive IR recombination reads from cancer and adjacent normal tissue samples representing 22 Kenyan BC patients...
March 8, 2023: Breast Cancer Research and Treatment
Patricia Mazzonetto, Fernanda Milanezi, Mariana D'Andrea, Silvia Martins, Priscilla M Monfredini, Juliana Dos Santos Silva, Eduardo Perrone, Darine Villela, Beatriz Schnabel, Viviane Nakano, Edenir Inez Palmero, Esteban Braggio, Thereza L Cavalcanti, Gustavo Guida, Michele P Migliavacca, Cristovam Scapulatempo-Neto, Ilana Zalcberg
We determined the frequency and mutational spectrum of BRCA1 and BRCA2 in a series of patients at high risk for developing breast cancer from Brazil. A total of 1267 patients were referred for BRCA genetic testing, and no obligation of fulfilling criteria of mutation probability methods for molecular screening was applied. Germline deleterious mutations in BRCA1/2 (i.e., pathogenic/likely pathogenic variants) were identified in 156 out of 1267 patients (12%). We confirm recurrent mutations in BRCA1/2, but we also report three novel mutations in BRCA2, not previously reported in any public databases or other studies...
March 7, 2023: Breast Cancer Research and Treatment
Anita Mamtani, Daniel D Sjoberg, Alain Vincent, Behfar Ehdaie, Deepak Malhotra, Andrew Vickers, Monica Morrow
PURPOSE: Despite the lack of any oncologic benefit, contralateral prophylactic mastectomy (CPM) use among women with unilateral breast cancer is increasing. This patient-driven trend is influenced by fear of recurrence and desire for peace of mind. Traditional educational strategies have been ineffective in reducing CPM rates. Here we employ training in negotiation theory strategies for counseling and determine the effect on CPM rates. METHODS: In consecutive patients with unilateral breast cancer treated with mastectomy from 05/2017 to 12/2019, we examined CPM rates before and after a brief surgeon training in negotiation skills...
March 7, 2023: Breast Cancer Research and Treatment
Carl Sars, Helena Sackey, Jan Frisell, Paul W Dickman, Fredrik Karlsson, Isabelle Kindts, Gustavo Nader Marta, Ruffo Freitas-Junior, Tove Filtenborg Tvedskov, Loay Kassem, Ahmed S Ali, Hanna Ihalainen, Mathias Neron, Michalis Kontos, Orit Kaidar-Person, Icro Meattini, Anne Brecht Francken, Frederieke van Duijnhoven, Ingvild Ona Moberg, Tanja Marinko, Attila Kollar, Mahbubl Ahmed, Dennis Remoundos, Jenny Banks, Reshma Jagsi, Lesly A Dossett, Ebba K Lindqvist
PURPOSE: Phyllodes tumors of the breast are rare fibroepithelial lesions that are classified as benign, borderline or malignant. There is little consensus on best practice for the work-up, management, and follow-up of patients with phyllodes tumors of the breast, and evidence-based guidelines are lacking. METHODS: We conducted a cross-sectional survey of surgeons and oncologists with the aim to describe current clinical practice in the management of phyllodes tumors...
March 6, 2023: Breast Cancer Research and Treatment
Hanfang Jiang, Huiping Li, Guohong Song, Lijun Di, Bin Shao, Ying Yan, Xiaoran Liu, Yifei Chen, Ruyan Zhang, Ran Ran, Yaxin Liu, Xinyu Gui, Nan Wang, Huan Wang
PURPOSE: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) heavily pretreated with anthracycline and taxanes. METHODS: In this single-arm, phase II study, patients with HER2-negative MBC previously treated with anthracycline and taxanes as second- to fifth chemotherapy received PLD (Duomeisu® , generic doxorubicin hydrochloride liposome) 40 mg/m2 every 4 weeks until disease progression, unacceptable toxicity, or completion of six cycles...
March 6, 2023: Breast Cancer Research and Treatment
Jui-Hung Tsai, Chung-Liang Li, Dah-Cherng Yeh, Chin-Sheng Hung, Chih-Chiang Hung, Chin-Yao Lin, Yao-Lung Kuo
PURPOSE: This study aimed to compare the effectiveness and safety of pegylated liposomal doxorubicin (PLD)-based and epirubicin-based combination therapy regimen as neoadjuvant therapy for early breast cancer. METHODS: Patients with stage I-III breast cancer who underwent neoadjuvant therapy followed by surgery between January 2018 and December 2019 were retrospectively reviewed. The primary outcome was pathological complete response (pCR) rate. The secondary outcome was radiologic complete response (rCR) rate...
March 4, 2023: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.